文献速递胸部肿瘤放疗放疗物理与技术

高危肺癌队列的大分割与立体定向体部质子放疗:质子协作组前瞻性登记研究

Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-09-15

基于多机构前瞻性登记数据,评估≤15次质子束治疗(PBT)大分割/立体定向体部放疗(SBRT/HFRT)对高危肺癌的安全性和疗效。104例患者110个肿瘤中,1年和2年局部控制率分别为83.1%和77.4%,无≥3级毒性,高危亚组间局部控制无差异。

要点

  • 高危肺癌质子SBRT/HFRT的1年和2年局部控制率为83.1%和77.4%。
  • 肿瘤大小、超中央位置或再照射亚组间局部控制无差异。
  • 最常见毒性为咳嗽(40%)和呼吸困难(34.5%),无≥3级事件。

核心结论

  • 质子SBRT/HFRT在高危肺癌队列中1年和2年局部控制率为83.1%和77.4%,无≥3级毒性,高危亚组局部控制相似。

研究设计与样本

  • 前瞻性多机构登记研究,纳入104例接受≤15次质子束治疗(PBT)的肺癌患者共110个肿瘤。
  • 合格方案包括4-5次分割且每次≥10Gy(总≥48Gy)或8-15次分割且每次≥3.5Gy(总≥52.5Gy)。
  • 局部控制采用累积发生率估计(死亡为竞争风险),Fine-Gray模型用于亚组比较。

主要发现

  • 83.6%为非小细胞肺癌,32.7%肿瘤≥4 cm,41.8%为超中央位置,30%为再照射。
  • 最常见方案为60Gy/15次(40%)和50Gy/5次(17.2%),71.8%接受调强质子治疗。
  • 1年和2年局部控制率分别为83.1%和77.4%,肿瘤大小、超中央位置或再照射亚组间无差异。
  • 内大体肿瘤体积接受95%剂量与局部控制改善相关(p = 0.007)。

关键数值与推荐

  • 合格分割方案:4-5次且每次≥10Gy(总≥48Gy)或8-15次且每次≥3.5Gy(总≥52.5Gy)。
  • 内大体肿瘤体积接受95%剂量与局部控制改善相关(p = 0.007)。

临床怎么用

  • 质子SBRT/HFRT可用于高危肺癌(大肿瘤、超中央位置、再照射),局部控制可接受且无≥3级毒性。
  • 关注内大体肿瘤体积接受95%剂量以确保局部控制。

局限性

  • 生存期和随访时间短限制了对结果的评估。
  • 尽管为前瞻性登记,许多患者可靠的长期随访数据仍有限,部分限制了结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer is commonly treated with stereotactic body radiotherapy (SBRT) and hypofractionated RT (HFRT). Delivering these ablative regimens with proton beam therapy (PBT) may yield dosimetric and clinical advantages, particularly for high-risk cases. We evaluated safety and efficacy of SBRT/HFRT PBT for lung tumors, including unfavorable subgroups. METHODS: Adults with lung tumors treated with PBT ≤15 fractions were identified from a prospective, multi-institutional registry. Eligible regimens included 4-5 fractions at ≥10Gy/fraction (≥48Gy total) or 8-15 fractions at ≥3.5Gy/fraction (≥52.5Gy total). Local control (LC) was estimated using cumulative incidence with death as a competing risk, and Fine-Gray models were used for subgroup comparisons. RESULTS: 104 patients with 110 tumors (83.6% non-small cell lung cancer) were included: 32.7% ≥4 cm, 41.8% ultracentral, and 30% re-irradiated. Most common regimens were 60Gy/15 fractions (40%) and 50Gy/5 fractions (17.2%); 71.8% received intensity-modulated PBT. 1-and 2-year LC rates were 83.1% and 77.4%, with no difference by tumor size, ultracentral location, or re-irradiation. Internal gross tumor volume receiving 95% of dose was associated with improved LC (p = 0.007). Most common toxicities were cough (40%) and dyspnea (34.5%), with no Grade ≥ 3 events. CONCLUSIONS: In the largest prospectively enrolled report of SBRT/HFRT via intensity-modulated PBT for a high-risk lung tumor cohort, 1- and 2-year LC rates were 83.1% and 77.4%, with no grade ≥ 3 toxicities. LC was similar among high-risk subgroups. However, short survival and follow-up durations limited assessment of the findings. Despite the prospective registry, reliable long-term follow-up data remained limited for many patients, somewhat restricting result interpretation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Allen AJ, Simone CB, Sun K, et al. Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry. Clin Transl Radiat Oncol. 2026. PMID: 42787797. doi:10.1016/j.ctro.2026.101291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。